#Canada #Toronto #Frontage Laboratories #Frontage Holdings #Dr. Abdul Mutlib

Frontage Holdings Expands Its Operations in Canada

In a strategic move to broaden its global service offerings, Frontage Holdings Corporation has declared its latest expansion into Canada with the appointment of Dr. Abdul Mutlib as President of Frontage Laboratories, Canada. This development signifies Frontage's commitment to enhancing its presence and impact in the biopharmaceutical sector across the region, specifically targeting the burgeoning biotech industry.

Dr. Mutlib, who has an impressive career spanning over 35 years in research and development within large pharmaceutical firms and contract research organizations (CROs), is well-placed to guide the company towards achieving ambitious growth targets in the Canadian market. Besides his new role, he will continue to manage his responsibilities as Chief Scientific Strategy Officer at Frontage Laboratories, focusing on strengthening scientific initiatives and fostering innovative strategies that align with Frontage’s overarching goals.

The Canadian operations will be centered in Toronto and Vancouver, thriving cities that serve as hubs for biotechnology and pharmaceutical innovation. Dr. Mutlib will report directly to Dr. Wentao Zhang, the Co-Chief Executive Officer of Frontage Holdings. Dr. Zhang expressed confidence in Dr. Mutlib's leadership, highlighting his integral role in Frontage’s growth trajectory over the past years.

“Abdul's leadership and experience have been vital to Frontage's growth over the last several years. His vision and strong leadership qualities will drive our success and expansion in Canada,” stated Dr. Zhang.

Dr. Mutlib, welcoming this new challenge, stated, “I am deeply honored by this opportunity. I have full confidence in our Canadian team, and together, we aim to expand our services and significantly grow the business in the coming years. I’m excited to collaborate with Canadian authorities and establish Frontage as a leading provider of comprehensive, high-quality R&D services.”

This expansion marks a crucial phase for Frontage as they seek to establish themselves as a key partner for various biotechnology companies in Canada. With the growing demand for expertise in drug development and regulatory challenges, the company aims to offer robust solutions that support the needs of the evolving industry landscape.

Moreover, Frontage provides a vast array of integrated services, from drug discovery to late-phase clinical processes, enabling biopharmaceutical firms to realize their development ambitions. Their comprehensive portfolio includes drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety, and toxicology assessments along with early-phase clinical studies.

Frontage has already supported several biotechnology firms and major pharmaceutical companies as they navigated the development of new molecules and facilitated successful regulatory submissions on a global scale.

As Frontage approaches this new chapter in Canada, both the management and the team remain highly optimistic about the future prospects. The commitment to innovation and excellence is clear, and under Dr. Mutlib’s guidance, Frontage is poised to make significant contributions toward Canada’s goal of becoming a leading hub for biotechnology and pharmaceutical advancements.

For more information on Frontage and its services, please visit www.frontagelab.com.